Influence of target hemoglobin in dialysis patients on morbidity and mortality

Kidney International, Supplement

Volumn 61, Issue 80, 2002, Pages

  Collins, Allan J ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Anemia; Blood hematocrit; Dialysis

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

CONFERENCE PAPER; HEART DISEASE; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; TREATMENT OUTCOME; ANEMIA; CHRONIC KIDNEY FAILURE; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RENAL DIALYSIS; RISK FACTORS;

EID: 0035999922     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.61.s80.9.x     Document Type: Conference Paper

References (29)

1. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III multicenter clinical trial
2. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
3. Cardiovascular mortality of patients with polycystic kidney disease on dialysis: Is there a lesson to learn?
4. In search of an optimal hematocrit level in dialysis patients: Rehabilitation and quality-of-life implications
5. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities
6. Trends in anemia treatment with erythropoietin usage and patient outcomes
7. Hematocrit levels and hospitalization risks in hemodialysis patients
8. Hematocrit level and associated mortality in hemodialysis patients
9. Hematocrit levels and associated Medicare expenditures
10. Target hemoglobin in patients with renal failure
11. Normalization of haemoglobin: Why not?
12. Higher target haemoglobin level and early anaemia treatment: Different or complementary concepts?
13. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
14. Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study
15. Iron and the sex difference in heart disease risk
16. The iron paradigm of ischemic heart disease
17. Stored iron and ischemic heart disease: Empirical support for a new paradigm
18. Iron versus cholesterol: Perspectives on the iron and heart disease debate
19. Iron overload augments the development of atherosclerotic lesions in rabbits
20. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients
21. Iron metabolism during infection and neoplasia
22. Transferrins and heme-compounds as iron sources for pathogenic bacteria
23. Iron, infections, and anemia of inflammation
24. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients
25. Anemia in hemodialysis patients: Variables affecting this outcome predictor
26. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry
27. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%
28. Trends in anemia at initiation of dialysis in the United States